Clinical trial
A Phase 1/2 Study of Belantamab Mafodotin in Combination With Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT04808037 is registered in ClinicalTrials.gov with Hellenic Society of Hematology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Belantamab Mafodotin in Combination With Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Lead sponsor
- Hellenic Society of Hematology
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- February 22, 2021
- Completion date
- November 8, 2028
- Enrollment
- 66 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.